Data from the phase 3 study confirmed the lot consistency, immunogenicity, safety, and tolerability of a toxoid-based Clostridioides difficile vaccine. Neutralizing antibody responses 1 month after ...
A new therapeutic method using human antibodies to neutralize toxins was found to prevent Clostridium difficile-induced death in hamsters say researchers from New Jersey and Massachusetts. C.
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the two pivotal Phase 3 clinical studies for bezlotoxumab, its ...
Clostridiodes difficile infection has become a leading cause of severe, sometimes fatal diarrheal illness, with the bacterium's toxins causing the damage. New work cements our knowledge of how C. diff ...
BOSTON – Estimated to cause almost half a million infections per year, the bacterium Clostridioides difficile, also known as C. difficile or “C. diff,” can cause diarrhea and inflammation of the large ...
CHICAGO, Ill. (WPVI) -- A new drug to treat C. Difficile, also known as C. Diff, is getting C. diff is a common bacterial infection of the gut, and it can be deadly. In two Phase 3 clinical trials, an ...
Clostridium difficile infection is one of the most common healthcare-associated infections in adults in the United States. Older Americans are especially vulnerable to CDI, 2 and this infection has ...
Researchers at Vanderbilt University Medical Center have obtained the crystal structure of a toxin from the bacterium Clostridium difficile ("C. diff") -- the leading cause of hospital-acquired ...
Isolating asymptomatic C. diff carriers linked with lower incidence of infection Screening and isolating asymptomatic Clostridium difficile carriers was associated with a reduction in incidence of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback